Truist analyst David MacDonald lowered the firm’s price target on Quest Diagnostics to $145 from $150 and keeps a Hold rating on the shares. The company’s Q4 results were somewhat mixed, featuring top-line strength and solid base business trends while margins came shy of the firm’s estimates, the analyst tells investors in a research note. Truist adds however that the company’s financial flexibility remains solid, and it expects an ongoing tailwind from health system opportunities and a robust pipeline of potential M&A.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics Announces 5.6% Quarterly Dividend Hike
- Quest Diagnostics increases quarterly dividend 5.6% to 75c per share
- Quest Diagnostics sees FY24 adjusted EPS $8.60-$8.90, consensus $8.99
- Quest Diagnostics reports Q4 EPS $2.15, consensus $2.11
- Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share